Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Murepavadin - Polyphor

Drug Profile

Murepavadin - Polyphor

Alternative Names: POL 7080; POL 7080 acetate; RG 7929; RO 7033877

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor
  • Class Antibacterials; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pseudomonal infections
  • No development reported Gram-negative infections

Most Recent Events

  • 17 Jul 2019 Polyphor terminates a phase III PRISM-MDR trial in Brazil, Croatia, Estonia, France, Greece, Hungary, Ireland, Israel, Mexico, South Africa, South Korea, Spain, Thailand and USA due to rise of creatinine concentration in the serum (NCT03409679)
  • 17 Jul 2019 Polyphor terminates a phase III PRISM-UDR trial in Pseudomonal infections (Combination therapy) in USA, Czech Republic, France, Israel, Lithuania and Hungary, due to rise of creatinine concentration in the serum (NCT03582007)
  • 20 Jun 2019 Polyphor plans a clinical trial for inhaled formulation of murepavadin for Pseudomonal infections in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top